Diagnostic application of CK-MB mass determination.
Recent advances in analytic techniques have increased the diagnostic value of creatine kinase MB (CK-MB), enabling earlier and more sensitive results. The CK-MB mass immunoassays, that utilise the monoclonal anti-CK-MB in conjunction with anti-M or anti-B antibodies, are able to measure accurately small changes during the early hours after myocardial infarction (MI). CK-MB has two main limitations in diagnosing MI neither of which however undermines its established clinical value: CK-MB is not perfectly specific to cardiac injury, with increase occurring also during massive musculoskeletal injury; furthermore, the early release pattern of CK-MB limits its value for the late MI diagnosis. For the foreseeable future evidence is compelling for greater access to rapid testing capabilities in emergency situations, using protocols incorporating CK-MB mass evaluation together with other biochemical markers, i.e. myoglobin and troponins.
Panteghini
M
M
Clinical Chemistry and Enzymology Section, Spedali Civili, Brescia, Italy.
D003402:Creatine Kinase / Q000737:chemistry; D006801:Humans; D007527:Isoenzymes; D008970:Molecular Weight; D009203:Myocardial Infarction / Q000175:diagnosis; D015425:Myocardial Reperfusion; D011379:Prognosis; D012680:Sensitivity and Specificity
D007527:Isoenzymes; D003402:Creatine Kinase